Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 25, 2023.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
With limited options available in perimenstrual catamenial epilepsy, a phase 4 study seeks to understand whether an FDA-approved agent for focal onset seizures can effectively treat women with difficult-to-manage disease.
In this Mind Moments Podcast episode, Erin Furr-Stimming, MD, FAAN, FANA, a professor of neurology at McGovern Medical School of UTHealth Houston, discussed the recent expanded indication of valbenazine (Ingrezza; Neurocrine Biosciences) to include the treatment of chorea associated with Huntington disease.
In this week's Q&A interview, the associate staff member in the department of neurology at Cleveland Clinic provided perspective on a recently published phase 1 study assessing deep brain stimulation in individuals with chronic poststroke hemiparesis.
Experts—Tom Leist, MD; Olga Thon, MD; David B. Duncan, MD; Clyde E. Markowitz, MD— share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.
Jason Freeman, MD, MBA, and Arsalan Syed, PhD, discuss highlights from the session “Multiple Sclerosis Disease Modifying Treatments” presented at AAN 2023. Sponsored By Novartis